Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2016

View Archived Issues

Bayer Schering Pharma divulges factor XIa inhibitors

Changzhou Yinsheng Pharmaceutical and Sichuan University patent HCV NS4B inhibitors

Jiangsu Carefree, Nanjing Carephar and Nanjing Carephar Shenghui report JAK inhibitors

Intra-Cellular Therapies discloses PDE1B inhibitors

FORMA Therapeutics introduces isocitrate dehydrogenase inhibitors

UChicago and Evelo Biosciences sign agreement to develop cancer therapy

Ironwood reports first-in-human results for cardiovascular disease candidate IW-1973

FDA accepts IND application for Adaptimmune affinity enhanced T-cell therapy targeting AFP

Immunovaccine and Leidos to collaborate on a Zika virus vaccine candidate

Pfizer and IBM to develop remote monitoring system for Parkinson's disease patients

Juno Therapeutics and Wuxi AppTec start new cell therapy-focused company in China

Galapagos begins phase IIa study of GLPG-1690 in IPF

New biomarker panel described for Hirschprung disease

S100-A4 overexpression shows promise as a prognostic biomarker for signet-ring cell carcinoma

Cynata Therapeutics's MSC product shows promising results in murine model of GvHD

Two of Volition Rx's blood-based biomarker assays receive CE Mark

Large, multinational studies of anti-HIV antibody VRC-01 launched by NIH

E.U. approves subcutaneous formulation of epoetin alfa product Binocrit for nephrology use

Cardiac MyBP-C is a highly senstitive biomarker of myocardial injury

FDA places clinical hold on IONIS-TTRRx study

IMT-001, an immunotherapy for the treatment of early-onset type 1 diabetes

AstraZeneca and Lilly announce continuation of pivotal Alzheimer's disease trial

FDA committee recommends accelerated approval of Ocaliva

DURECT announces changes in phase III trial PERSIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.